Risvutatug rezetecan Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Also known as: GSK5764227, HS-20093

Pipeline

Early 1: 1Phase 1/2: 1

Top Sponsors

Nader Sanai1
GlaxoSmithKline1

Indications

Cancer2
Brain Metastasases1
Gastrointestinal Neoplasms1
Glioblastoma (GBM)1

Phoenix, Arizona1 trial

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

St. Joseph's Hospital and Medical Center

Early 1

Los Alamitos, California1 trial

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

GSK Investigational Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.